Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 13;28(3):e171–e174. doi: 10.1093/oncolo/oyac265

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Real-world mCRC patients receiving second and third lines of anti-BRAF/EGFR combinatory regimens have different outcomes according to RNF43 and MSI status, consistent with Elez et al. (published cohort). Forest plots showing outcomes of all patients treated with anti-BRAF by RNF43 and MSI status for (A) PFS and (B) OS. Forest plots showing outcomes of MSS patients treated with anti-BRAF and no anti-BRAF by RNF43 status for (C) PFS and (D) OS.